Windlas Biotech Ltd
Windlas Biotech Ltd is a leading domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). The company manufactures both solid and liquid pharmaceutical dosage forms and provides a comprehensive range of CDMO services ranging from product discovery, product development, and commercial manufacturing of generic products, including complex generics.[1]
- Market Cap ₹ 1,754 Cr.
- Current Price ₹ 839
- High / Low ₹ 900 / 308
- Stock P/E 29.4
- Book Value ₹ 216
- Dividend Yield 0.48 %
- ROCE 18.1 %
- ROE 13.6 %
- Face Value ₹ 5.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 21.3% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 19.7%
Cons
- Company has a low return on equity of 12.4% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
274 | 315 | 320 | 288 | 329 | 428 | 466 | 513 | 631 | 661 | |
253 | 290 | 284 | 244 | 288 | 373 | 413 | 453 | 553 | 579 | |
Operating Profit | 20 | 25 | 36 | 44 | 41 | 55 | 53 | 60 | 78 | 82 |
OPM % | 7% | 8% | 11% | 15% | 12% | 13% | 11% | 12% | 12% | 12% |
1 | 4 | 5 | 2 | 1 | -29 | 7 | 10 | 13 | 15 | |
Interest | 7 | 5 | 5 | 4 | 2 | 1 | 1 | 1 | 1 | 1 |
Depreciation | 9 | 9 | 11 | 8 | 9 | 13 | 12 | 12 | 13 | 16 |
Profit before tax | 6 | 14 | 25 | 35 | 31 | 11 | 46 | 57 | 77 | 79 |
Tax % | 20% | 35% | 33% | 36% | 27% | 55% | 16% | 25% | 25% | |
5 | 9 | 17 | 22 | 22 | 5 | 39 | 43 | 58 | 60 | |
EPS in Rs | 8.14 | 16.41 | 30.24 | 35.05 | 35.03 | 7.81 | 17.69 | 20.05 | 27.95 | 28.61 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 20% | 20% | 20% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 14% |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 44% |
TTM: | 33% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 34% |
1 Year: | 135% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | 12% |
Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 11 | 10 | 10 |
Reserves | 132 | 141 | 158 | 188 | 210 | 193 | 384 | 392 | 440 |
53 | 62 | 43 | 30 | 27 | 32 | 7 | 5 | 4 | |
90 | 94 | 93 | 73 | 100 | 65 | 89 | 121 | 172 | |
Total Liabilities | 281 | 304 | 299 | 297 | 344 | 296 | 491 | 529 | 626 |
56 | 56 | 58 | 62 | 68 | 96 | 91 | 109 | 179 | |
CWIP | 9 | 15 | 11 | 5 | 0 | 0 | 8 | 15 | 6 |
Investments | 95 | 121 | 123 | 121 | 121 | 23 | 65 | 107 | 173 |
121 | 111 | 107 | 110 | 154 | 177 | 327 | 298 | 268 | |
Total Assets | 281 | 304 | 299 | 297 | 344 | 296 | 491 | 529 | 626 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
47 | 7 | 39 | 22 | 21 | 11 | 9 | 61 | 109 | |
-62 | -39 | -11 | -7 | -9 | -20 | -154 | -14 | -92 | |
38 | 5 | -25 | -8 | -6 | 1 | 130 | -44 | -15 | |
Net Cash Flow | 24 | -27 | 4 | 7 | 5 | -8 | -15 | 3 | 2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 74 | 70 | 68 | 79 | 72 | 68 | 87 | 83 | 79 |
Inventory Days | 49 | 62 | 44 | 38 | 85 | 55 | 71 | 84 | 57 |
Days Payable | 137 | 120 | 124 | 117 | 143 | 53 | 76 | 98 | 121 |
Cash Conversion Cycle | -14 | 13 | -12 | 0 | 13 | 70 | 82 | 69 | 15 |
Working Capital Days | -14 | 2 | 2 | 10 | 27 | 66 | 91 | 73 | 133 |
ROCE % | 10% | 13% | 18% | 14% | 19% | 15% | 14% | 18% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 20 Aug
- Recording Of Conference Call 14 Aug
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
13 Aug - Press Release on un-audited financial results for the quarter ended June 30, 2024
-
Announcement under Regulation 30 (LODR)-Investor Presentation
13 Aug - Results presentation for the quarter ended June 30, 2024
- Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30, 2024. 13 Aug
Annual reports
Concalls
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021Transcript PPT
-
Sep 2021TranscriptNotesPPT
Market Position
Windlas Biotech is amongst the top five players in the domestic pharmaceutical formulations, contract development, and manufacturing organization (CDMO) industry in India, in terms of revenues. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics. [1]